TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03228511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscope
Description: It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
Study: NCT03019237

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intranasal allergen
Description: intranasal allergen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: intranasal saline
Description: intranasal placebo
Study: NCT02996825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Given IV
Study: NCT00749138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: giving drug tamoxifen
Study: NCT02978027

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NIAAA Clinician's Guide
Study: NCT02996825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02978027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Study: NCT03876652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker with Closed Loop Stimulation (CLS)
Description: In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker with Closed Loop Stimulation (CLS)
Description: In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
Study: NCT03302962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Asthma Education
Description: One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted.
Study: NCT02544243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT03626948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1403
Description: Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
Study: NCT03886103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C labeled PXL770
Description: Single administration
Study: NCT00208793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3 combined
Description: Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
Study: NCT02376218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic 50% dextrose pleurodesis
Description: Intrapleural administration of 180ml of hypertonic dextrose solution.
Study: NCT01270451

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle intervention to prevent weight regain
Description: To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
Study: NCT01509729

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham operation
Description: A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
Study: NCT03930355

Intervention type: OTHER
Intervention: Blood transfusion
Description: Patients who received blood transfusion in the perioperative period

Intervention type: OTHER
Intervention: Control
Description: Patients who did not receive blood transfusion in the perioperative period
Study: NCT00674648

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-Peptide-Specific T cells
Description: In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).~The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose.
Study: NCT02332226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Representational approach
Description: Representational approach to patient education
Study: NCT01286610

Intervention type: DEVICE
Group type: OTHER
Intervention: ProMedVi Vibrosphere
Description: vibration therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: schwa-medico MUSKELaktiv
Description: Electrical muscle stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Galileo Home Plus (ICU)
Description: vibration therapy
Study: NCT05063513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Experimental arm will undergo mobilisation with CY 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
Study: NCT03459560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyPill
Description: After the baseline enrollment and excluding non-eligible participants, we randomized villages to Polypill and control arms. Follow-ups are scheduled for 1, 3, and 6 months after the initial enrollment in the Polypill arm and every six months thereafter. For the minimal care arm, the follow-ups are arranged every six months.
Study: NCT01967966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Single IV dose
Study: NCT01417156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 150 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidoneone
Description: Existing treatment
Study: NCT01580605

Intervention type: DRUG
Intervention: somatropin
Description: Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment
Study: NCT03320902

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sudden death counselling
Description: The Sudden Death Counselling with included relatives at 1 month (+/-15 days) after the eventafter the event will be at the Europeen Georges Pompidou hospital in Paris.~The purpose of this Sudden Death Counselling is to provide to family members of sudden death victims information, support, referral and follow-up services relating to sudden death and their grief, if needed.~The bereaved people will tell their experience. The Sudden Death Counselling would help them to integrate life's losses by companioning them.~Cardiologist and psychologists will be present to listen to their pain and try to bring comfort by answering to their questionings.
Study: NCT01198769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix TM
Description: Oral, 2 doses
Study: NCT03175705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HCC antigens-specific CD8+ T lymphocytes
Description: Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10\^7/m2 Loading Dose 2: 6x10\^7/m2 Loading Dose 3: 9x10\^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
Study: NCT01521832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 5 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 25 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 75 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 150 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 300 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 600 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 300 mg single oral dose (females)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg multiple oral dose
Study: NCT01509729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroscopic surgery
Description: A randomized group of patients was given small patches with active 5% lidocaine.
Study: NCT01521832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 300 mg multiple oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg BID multiple oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg BID multiple oral dose (females)
Study: NCT04653012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial macro-microelectrode recording
Description: Additionnally to clinical macroelectrodes, Benkhe-Fried depth macro-microelectrodes will be implanted and recorded during the pre-surgical investigation of epileptic patients
Study: NCT00917748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL(XRP6976) + MODAFINIL
Description: arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DOCETAXEL(XRP6976) + MODAFINIL
Description: arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Modafinil
Description: Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
Study: NCT01555632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT03335475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Lifestyle Intervention
Description: Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Monitoring
Description: A physical activity monitor (Fitbit) will be provided to both groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Monitoring
Description: A physical activity monitor (Fitbit) will be provided to both groups.
Study: NCT01030289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real tDCS
Description: transcranial direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real tDCS
Description: transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: transcranial direct current stimulation
Study: NCT00459277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
Study: NCT00658723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Pad
Description: Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL™
Description: Absorbable hemostat
Study: NCT03792399

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: feedback counseling
Description: Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feedback counseling
Description: Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.
Study: NCT01405820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab IV
Description: natalizumab for IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab IV
Description: natalizumab for IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab SC
Description: natalizumab for Subcutaneous Injection
Study: NCT00047073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.~Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.~Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.~Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.~Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection.
Study: NCT02089672

Intervention type: DEVICE
Intervention: Catheter ablation
Description: This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
Study: NCT00047073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.~Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.~If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.~Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.~If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented.
Study: NCT03609385

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: In patients eligible for participation in the study coronary angiography, echocardiography and EKG will be performed systematically.
Study: NCT04016129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
Description: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
Study: NCT01405820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab SC
Description: natalizumab for Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab SC
Description: natalizumab for Subcutaneous Injection
Study: NCT03774628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chengdu Kanghua (one booster shot)
Description: A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chengdu Kanghua (two booster shots)
Description: A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
Study: NCT02504073

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04236791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
Study: NCT01405820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Placebo
Description: Intravenous placebo to natalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Placebo
Description: Intravenous placebo to natalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Placebo
Description: Subcutaneous placebo to natalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Placebo
Description: Subcutaneous placebo to natalizumab
Study: NCT02152020

Intervention type: BEHAVIORAL
Intervention: Survey
Study: NCT04383704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))
Description: A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New Dietary pattern ( Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND))
Description: A new brain-protection pattern that has been designed after the Mediterranean and DASH diet to improve some of their dietary factors to have the highest impact on brain health and cognitive performance.
Study: NCT02370706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIM447
Description: pan-pim inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIM447
Description: pan-pim inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIM447
Description: pan-pim inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIM447
Description: pan-pim inhibitor
Study: NCT06018675

Intervention type: OTHER
Intervention: kinesiotherapy
Description: Group 1: Kinesiotherapy Group 2: Dry needling Group 3: lidocain injection
Study: NCT04236791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
Study: NCT02676479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine Lavage Group
Description: The PI places the Lavage Catheter per instructions for use~* Use of a tenaculum or cervical stitch is required~* Use of saline to wash the cervix is required~* Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix.
Study: NCT03274843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity of everyday life
Description: Kitchen workshop
Study: NCT01815164

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: Gut-directed hypnotherapy administered by an experienced hypnotherapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Educational intervention vith education regarding Irritabel bowel Syndrome.